- Home
- TWST vs IMTX Comparison
TWST vs IMTX Comparison
Compare TWST & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWST | IMTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TWST | IMTX |
|---|---|---|
| Price | $46.04 | $9.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $47.89 | $19.25 |
| AVG Volume (30 Days) | ★ 1.4M | 359.8K |
| Earning Date | 02-02-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $391,557,000.00 | $99,445,031.00 |
| Revenue This Year | $16.77 | N/A |
| Revenue Next Year | $15.06 | $19.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.59 | N/A |
| 52 Week Low | $23.30 | $3.30 |
| 52 Week High | $54.74 | $12.41 |
Technical Indicators
Market Signals| Indicator | TWST | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.16 | 51.05 |
| Support Level | $39.66 | $9.38 |
| Resistance Level | $43.34 | $10.10 |
| Average True Range (ATR) | 2.50 | 0.51 |
| MACD | 0.16 | 0.02 |
| Stochastic Oscillator | 77.41 | 47.97 |
Price Performance
Historical ComparisonAbout TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.